中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2010年
2期
26-27
,共2页
胃癌%骨髓抑制
胃癌%骨髓抑製
위암%골수억제
Stomach neoplasms%Myelosuppression
目的 比较FOLFOX4与DCF方案治疗老年晚期胃癌的疗效和不良反应.方法 将43例经病理检查确诊的晚期胃癌的老年患者随机分为两组.FOLFOX4组19例,给予奥沙利铂85 mg/m2静脉注射,第1天;亚叶酸钙(CF)200 mg/m2静脉滴注2 h,第1～2天;5-氟脲嘧啶(5-FU)400 mg/m2,静脉推注,继之600 mg/m2,持续静脉点滴22 h,第1～2天,14 d为1个周期.DCF组24例,给予多西他赛75 mg/m2静脉滴注2 h,第1天;顺铂总量75 mg/m2,分3天;5-氟脲嘧啶(5-FU)750 mg/m2持续静脉点滴,第1～5天,每3周为1个周期.每2个周期评价疗效,对两组缓解率、无进展生存期、总生存期及不良反应进行比较.结果 FOLFOX4组与DCF组的缓解率、无进展生存期、总生存期差异均无统计学意义(P＞0.05),但两组化疗后骨髓抑制方面差异有统计学意义(P=0.037).结论 FOLFOX4方案在老年晚期胃癌患者中不仅疗效与DCF方案相当,且具有不良反应小的优越性.
目的 比較FOLFOX4與DCF方案治療老年晚期胃癌的療效和不良反應.方法 將43例經病理檢查確診的晚期胃癌的老年患者隨機分為兩組.FOLFOX4組19例,給予奧沙利鉑85 mg/m2靜脈註射,第1天;亞葉痠鈣(CF)200 mg/m2靜脈滴註2 h,第1～2天;5-氟脲嘧啶(5-FU)400 mg/m2,靜脈推註,繼之600 mg/m2,持續靜脈點滴22 h,第1～2天,14 d為1箇週期.DCF組24例,給予多西他賽75 mg/m2靜脈滴註2 h,第1天;順鉑總量75 mg/m2,分3天;5-氟脲嘧啶(5-FU)750 mg/m2持續靜脈點滴,第1～5天,每3週為1箇週期.每2箇週期評價療效,對兩組緩解率、無進展生存期、總生存期及不良反應進行比較.結果 FOLFOX4組與DCF組的緩解率、無進展生存期、總生存期差異均無統計學意義(P＞0.05),但兩組化療後骨髓抑製方麵差異有統計學意義(P=0.037).結論 FOLFOX4方案在老年晚期胃癌患者中不僅療效與DCF方案相噹,且具有不良反應小的優越性.
목적 비교FOLFOX4여DCF방안치료노년만기위암적료효화불량반응.방법 장43례경병리검사학진적만기위암적노년환자수궤분위량조.FOLFOX4조19례,급여오사리박85 mg/m2정맥주사,제1천;아협산개(CF)200 mg/m2정맥적주2 h,제1～2천;5-불뇨밀정(5-FU)400 mg/m2,정맥추주,계지600 mg/m2,지속정맥점적22 h,제1～2천,14 d위1개주기.DCF조24례,급여다서타새75 mg/m2정맥적주2 h,제1천;순박총량75 mg/m2,분3천;5-불뇨밀정(5-FU)750 mg/m2지속정맥점적,제1～5천,매3주위1개주기.매2개주기평개료효,대량조완해솔、무진전생존기、총생존기급불량반응진행비교.결과 FOLFOX4조여DCF조적완해솔、무진전생존기、총생존기차이균무통계학의의(P＞0.05),단량조화료후골수억제방면차이유통계학의의(P=0.037).결론 FOLFOX4방안재노년만기위암환자중불부료효여DCF방안상당,차구유불량반응소적우월성.
Objective To compare the efficacy and toxicity between FOLFOX4 regimen(oxliplatin +CF + 5-FU) and DCF regimen (docetaxel + Cisplatin + 5-FU)for aged advanced gastric cancer. Methods Clinical data of 43 chemotherapy -naive aged patients with advanced gastric cancer were analyzed. Of the 43 patients ,19 patients were treated with FOLFOX4 regimen,24 patients were treated with DCF regimen. The patients in FOLFOX4 group received intravenous infusion of L- OHP(85 mg/m2)at day 1 ,bolus injection of 5 FU(400 mg/m2)at days 1 -2,and continuous intravenous infusion of 5 -FU (600 mg/m2)for 22 h at days 1-2;14 days as one cycle. The patients in DCF group received administration of docetaxel (75 mg/m2) at day 1,intravenous infusion of DDP (75 mg/m2) at days 1-3, and intravenous infusion of 5-FU (750 mg/m2) at days 1 -5 ;21 days as one cycle.After 2- 3 cycles of treatment,the remission rate ,time to disease progression (TTP) ,overall survival (OS)were compared. Results There were no statistic significance in RR,TTP,OS ,but the difference was statistical in myelosuppression. Conclusions FOLFOX4 regimen does not only have a good therapeutic effect as same as DCF but also the hematologic toxicities is better than DCF regimen.
